“Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials”, J of Skin, vol. 5, no. 1, p. s11, Jan. 2021, doi: 10.25251/skin.5.supp.11.